 |
| Anticipated Growth of Scopolamine Market to Reach US$ 675.6 Million with a 4.8% CAGR by 2030: Key Players Include GlaxoSmithKline plc, Novartis AG, Perrigo Company plc, Caleb Pharmaceuticals, Inc. |
The Scopolamine Market is poised for substantial growth, with an estimated value of US$ 462.7 million in 2022 and a projected CAGR of 4.8% from 2022 to 2030, according to a recent report by Coherent Market Insights.
Leading Companies in the Scopolamine Market:
- Baxter International Inc.
- GlaxoSmithKline plc
- Novartis AG
- Perrigo Company plc
- Caleb Pharmaceuticals, Inc.
- Myungmoon Pharma Co. LTD.
- Alchem International
- Phytex Australia
- Centroflora-Cms
- Alkaloids of Australia
- Fine Chemicals Corporation
Key Market Developments:
1. Breakthrough in Motion Sickness Treatment: In August 2023, Defender Pharmaceuticals presented promising results from their Phase 3 motion sickness trial at the Military Health System Research Symposium (MHSRS). The trial revealed that DPI-386, an intranasally administered scopolamine HBr, effectively prevented or alleviated motion sickness. Defender Pharmaceuticals intends to continue the development program and seek FDA approval for intranasal scopolamine.
2. Advancement in Emergency Treatment: In October 2022, Aktiv Pharma Group secured a procurement contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a scopolamine hydrobromide autoinjector, aiming for U.S. Food and Drug Administration (FDA) approval. This initiative is part of Aktiv's strategy to enhance its emergency treatment portfolio, which includes scopolamine, atropine, pralidoxime chloride (2-PAM), atropine/2-PAM dual-injection, and tranexamic acid (TXA).
3. Effective Motion Sickness Prevention: In July 2022, Defender Pharmaceuticals reported positive results from their phase 3 clinical trial assessing intranasal scopolamine for motion sickness prevention. The trial demonstrated that intranasal scopolamine significantly reduced nausea and vomiting compared to a placebo. This paves the way for Defender Pharmaceuticals to submit a New Drug Application (NDA) to the FDA for intranasal scopolamine approval.
4. NDA Submission for Motion Sickness: Also in July 2022, Defender Pharmaceuticals submitted an NDA to the FDA for intranasal scopolamine, seeking approval for preventing nausea and vomiting induced by motion in adults. This marks a crucial milestone for Defender in bringing an intranasal scopolamine product to market.
Scopolamine Market Report Overview:
Market Size and Growth:
- Market Value in 2023: USD 462.7 Million
- Projected Revenue in 2030: USD 675.6 Million
- Growth Rate: CAGR of 4.8%
- Base Year for Estimation: 2022
- Historical Data: 2017 – 2021
- Forecast Period: 2023 – 2030
Market Drivers:
1. Rising Motion Sickness Prevalence: The Scopolamine Market benefits from the increasing prevalence of motion sickness. As more individuals travel by various means, the demand for effective remedies to combat symptoms such as nausea, dizziness, and vomiting is on the rise. Scopolamine, known for its ability to reduce these symptoms, is becoming a preferred choice for motion sickness prevention and treatment.
2. Expanding Medical Applications: Scopolamine extends its utility beyond motion sickness, finding application in the treatment of Parkinson’s disease. Its potential to alleviate symptoms like tremors and muscle stiffness contributes to market growth. Healthcare professionals and patients are increasingly recognizing its benefits in managing these conditions.
Market Restraints:
1. Side Effects and Misuse: Despite its efficacy, scopolamine is not without side effects, which include dry mouth, blurred vision, drowsiness, and constipation. Severe reactions, such as hallucinations and memory impairment, can occur in some cases, impacting patient quality of life. Awareness of these potential side effects may limit its adoption.
2. Availability of Alternatives: Alternative medications and therapies exist for motion sickness treatment, such as over-the-counter antihistamines like dimenhydrinate and meclizine. Non-pharmacological approaches like acupressure and behavioral modifications are also used. The availability of these options presents competition to the scopolamine market, particularly among those seeking accessible or cost-effective alternatives.
In conclusion, the Scopolamine Market is on a growth trajectory, driven by its efficacy in treating motion sickness and its expanding therapeutic applications. However, challenges related to side effects and market competition from alternatives warrant careful consideration. The market's future will likely be shaped by ongoing research and development efforts to explore new applications for scopolamine.
إرسال تعليق